5 New Lung Cancer Clinical Trials for 2022
By Madeline May |
Clinical trials provide options for those diagnosed with serious conditions such as mesothelioma and lung cancer. We gathered 5 new lung cancer and mesothelioma clinical trials accepting patients in 2022.
Are There Any Clinical Trials for Lung Cancer?
Clinical trials allow patients to try emerging drugs, treatments, or medical devices for specific illnesses. Patients seeking treatment for cancers like mesothelioma and lung cancer can try different therapies during these tests. Clinical trials promise new options for late-stage cancer patients as well as those who have tried other treatments. These emerging treatments help patients and scientists as they study and research the effects of the therapies.
After receiving a severe condition diagnosis like that of lung cancer or mesothelioma, clinical trials may benefit you. We have rounded up five clinical trials accepting new patients in 2022.
S1800A Lung Cancer Clinical Trial
Patients diagnosed with advanced non-small cell lung cancer currently have limited options for therapy. A Phase II clinical trial led by Cedars-Sinai Cancer is part of the lung cancer precision medicine studies. This study combines chemotherapy with ramucirumab – an anti-angiogenesis drug. The drug’s goal is to weaken tumors and deprive them of nutrients. Additionally, the therapy utilizes immune checkpoint inhibitors combined with ramucirumab. The S1800A therapy promises a longer duration of response than patients that received standard care. Also, the combination therapy spares patients from the intense side effects of chemotherapy.
Patients with advanced non-small-cell lung cancer and interested in this clinical trial can contact the Southwest Oncology Group, the party responsible.
HLX10+ Chemotherapy Clinical Trial
A Phase III clinical study compares the safety and efficacy of HLX10+ chemotherapy in patients with extensive-stage small-cell lung cancer. It tests the results against placebo medicine in conjunction with chemotherapy for efficacy purposes. The trial will accept over 500 patients and assess tumors for up to 5 years after a patient’s enrollment.
The responsible party for the clinical trial is Shanghai Henlius Biotech. If you are interested in the clinical trial, contact the responsible party.
Surufatinib Clinical Trial
A Phase II clinical trial studies the efficacy and safety of Surufatinib combined with Toripalimab and chemotherapy. This clinical trial will assist patients with advanced non-squamous non-small cell lung cancer. The estimated enrollment is over 100 participants and aims to measure the progression-free survival (PFS) in participating patients for up to 24 months.
The primary contact for the clinical trial is Wenfeng Fang, MD. The therapy’s responsible party is Sun Yat-sen University. If you are diagnosed with advanced non-squamous non-small cell lung cancer and are interested in the trial, you can reach them at their email: [email protected]
HMPL-453 Clinical Trial
Patients with advanced malignant mesothelioma are eligible for this clinical trial. This clinical trial is a Phase II study to evaluate the efficacy, safety, and pharmacokinetic of HMPL-453 in patients with advanced malignant mesothelioma. Additionally, the test evaluates the overall response rate of HMPL-453 in patients with advanced malignant mesothelioma. The trial’s estimated enrollment is 27 participants, and the responsible party will measure patients for up to 6 months.
The primary contacts for the trial are Wenjuan Ding and Chen Yu, and the responsible party is Hutchison Medipharma Limited. You can participate by contacting the hosting parties at [email protected] or [email protected]
Bintrafusp Alfa Clinical Trial
This mesothelioma and lung clinical trial is in its second phase. Forty-seven patients will enroll in this trial to determine the efficacy and safety of Bintrafusp alfa (M7824) in advanced malignant pleural mesothelioma patients previously treated with platinum-based chemotherapy. The clinical test will evaluate progression-free survival (PFS) treatment success. The clinical trial host will assess the patients for up to 24 months afterward.
If you are interested in this mesothelioma clinical trial, the primary contact is Eva Pereira. You can contact the clinical trial hosts by email at [email protected]
What are my Options After Treatment?
Many patients with mesothelioma and lung cancer faced negligent asbestos exposure. Patients with a history of exposure may be eligible for legal action. Discover your options and stay up to date with Lung Cancer Center.
Disclaimer: None of the mentioned organizations are professionally affiliated with Lung Cancer Center.